- 24/7 Wall St.•3 hours ago
August 29, 2016: Here are four stocks trading with relatively heavy volume among 21 equities making new 52-week lows in Monday’s session. NYSE advancers led decliners by about 7 to 3 and Nasdaq advancers ...
- TheStreet.com•5 hours ago
Piper Jaffray said in a note Monday that Gilead Sciences (GILD) likely won't be impacted by GlaxoSmithKline's (GSK) potential new two-drug HIV regimen.
- Barrons.com•5 hours ago
As if Gilead Sciences (GILD) didn't have enough to worry about with competition in hepatitis C, now the Wall Street Journal is reporting that GlaxoSmithKline (GSK) is attempting to upend the HIV market too. Piper Jaffray's Joshua Schimmer and team don't seem to worried: We have had a number of incoming questions regarding the WSJ article highlighting a potential 2-drug HIV regimen based on GSK's dolutegravir. The costs of HIV resistance are very high, whereas the advantage of a 2-drug regimen over a 3-drug regimen (when both are 1-pill/once daily regimens anyways) is minimal.
Gilead Sciences Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||78.05 x 100|
|Ask||78.13 x 400|
|Day's Range||77.63 - 79.70|
|52wk Range||77.63 - 113.31|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||6.86|
|Avg Vol (3m)||10,159,655|
|Dividend & Yield||1.88 (2.36%)|